220.05; Figure 4). administered more than 8 weeks (MD SBP -4.69; 95 = 9.23, –0.16; when p

220.05; Figure 4). administered greater than 8 weeks (MD SBP -4.69; 95 = 9.23, –0.16; when p = 0.04) = 0 ; p = Subgroup evaluation exhibited that the = -4.69; reduced =significantly I = 0 ;AST 0.04) was lowered -9.23, 0.16; when AST was Subgroup evaluation S6 Figurethat the SBP was (Supplementary Fileexhibited weeks (MD = -4.69; 95 File=S6 Figure S4a,b indicate0.04) S4a). Supplementary File -9.23, -0.16; I2 = 0 ; p = was Figure (Supplementary File Figure 6 indicate the the administered for more6than 8 S4a). two administered for greater than eight dosage and duration -4.69; 95 CI CI subgroup analysisFile diverse weeks (MD =durationof AST. 6 Figure S4a,b 0 ; p = 0.04) on diverse dosageSupplementary File= -9.23, -0.16; I = indicate the subgroup evaluation on and of (Supplementary File six Figure S4a). Supplementary AST.6 Figure S4a,b indicate the (Supplementary six Figure S4a). File subgroup analysis on distinct dosage and duration of AST. subgroup evaluation on different dosage and duration of AST.Figure four. Forest plot from the impact of astaxanthin on systolic blood pressure [268,31]. Bold indicates systolic blood pressure [268,31]. Bold suggests Figure 4. Forest plot from the total information.Forest plot from the impact of astaxanthin on systolic blood pressure [268,31]. Bold indicates total information. Figure four. Forest plot in the impact of astaxanthin on systolic blood stress [268,31]. Bold means Figure four. total data. total Diastolic Blood Pressure (DBP) 3.4.four.information.3.4.four. Diastolic Blood Stress (DBP) The outcome of DBP was reported in 4 research [268,31], which involved 297 3.4.four.Theoutcome of DBP was reported in four research [268,31], which involved 297 sub3.four.four. Diastolic Blood Stress (DBP) Diastolic Blood Pressure manage jects (AST group = 154 subjects,(DBP) group = 143). Nonetheless, the pooled result did not subjects (AST group =DBP subjects, handle groupstudies [268,31],the pooled result 297 154 = 143). The outcome of DBP reduction soon after thefour studies Nevertheless, (MD = -2.09; 95 did The considerable was reported in administration of AST which involved 297 [268,31], which involved CI reveal anyoutcome of DBP was reported in four not reveal anygroup = 154 subjects, control groupadministration of AST pooled -2.09; 95 considerable DBP reduction just after the = 143). Nevertheless, the (MD = result did subjects (AST group = 154 subjects, control group = 143).Pascolizumab supplier Nevertheless, the pooled outcome did subjects (AST 2 CI -4.Bilobalide Apoptosis 87, 0.PMID:23613863 69; I = ten ; DBP reduction soon after the administration Figure S5,b indicate the not=reveal any significantp = 0.14; Figure five), Supplementary File 6of AST (MD = -2.09; 95 not reveal any substantial DBP reduction following the administration of AST (MD = -2.09; 95 subgroup 0.69; I2 = 10 ; p = 0.14; Figure five), Supplementary File six Figure S5,b indicate the CI = -4.87,analysis=on unique dosage and duration of AST, respectively. CI = -4.87, 0.69; I2 ten ; p = 0.14; Figure 5), Supplementary File six Figure S5,b indicate the subgroup analysis on various dosage and duration of AST, respectively. subgroup evaluation on distinctive dosage and duration of AST, respectively.Nutrients 2022, 14,12 ofNutrients 2022, 14, x FOR PEER Evaluation Nutrients 2022, 14, x FOR PEER Overview Nutrients 2022, 14, x FOR PEER Overview 4.87, =-10 the 0.69; I2 = ten ; p = 0.14; Figure five), Supplementary File S6 Figure S5a,b indicateof 14 subgroup analysis on distinctive dosage and duration of AST, respectively.10 of 14 10 ofFigure 5. Forest plot from the impact of astaxanthin on diastolic blood stress [268,31]. Bold mean.